share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股SEC公告 ·  09/30 06:24

Moomoo AI 已提取核心信息

Alterity Therapeutics, a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced the appointment of Abby Macnish Niven as its new Chief Financial Officer (CFO), effective September 30, 2024. Niven brings a wealth of experience from her previous roles in private wealth management at ANZ, UBS, and Ord Minett, and has consulted for various listed and unlisted companies on governance, finance, and corporate structure. She holds degrees in Commerce and Science from the University of Western Australia and is a Chartered Finance Analyst. Niven succeeds Phillip Hains, who had been serving as interim CFO since December 2023 and will continue as Company Secretary. Alterity's lead asset, ATH434, is currently undergoing two Phase 2 clinical trials for the treatment of Multiple System Atrophy, and the company also has a broad drug discovery platform for neurological diseases. The announcement was authorized by CEO David Stamler and is accompanied by forward-looking statements regarding the company's drug development program.
Alterity Therapeutics, a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced the appointment of Abby Macnish Niven as its new Chief Financial Officer (CFO), effective September 30, 2024. Niven brings a wealth of experience from her previous roles in private wealth management at ANZ, UBS, and Ord Minett, and has consulted for various listed and unlisted companies on governance, finance, and corporate structure. She holds degrees in Commerce and Science from the University of Western Australia and is a Chartered Finance Analyst. Niven succeeds Phillip Hains, who had been serving as interim CFO since December 2023 and will continue as Company Secretary. Alterity's lead asset, ATH434, is currently undergoing two Phase 2 clinical trials for the treatment of Multiple System Atrophy, and the company also has a broad drug discovery platform for neurological diseases. The announcement was authorized by CEO David Stamler and is accompanied by forward-looking statements regarding the company's drug development program.
生物技术公司Alterity Therapeutics专注于开发治疗神经退行性疾病的药物,宣布任命Abby Macnish Niven为其新的致富金融(临时代码)官员(CFO),任职日期为2024年9月30日。Niven在ANZ、UBS和Ord Minett的私人财富管理等之前的职务中积累了丰富经验,并为各种上市和非上市公司提供治理、财务和公司结构咨询。她毕业于西澳大学商学和科学专业,并是特许金融分析师。Niven接替了自2023年12月以来担任临时CFO的Phillip Hains,并将继续担任公司秘书。Alterity的主要资产ATH434目前正在进行两项针对多系统萎缩症治疗的2期临床试验,该公司还拥有广泛用于神经疾病的药物发现平台。该公告由CEO David Stamler授权发出,附有关于公司药物开发计划的前瞻性声明。
生物技术公司Alterity Therapeutics专注于开发治疗神经退行性疾病的药物,宣布任命Abby Macnish Niven为其新的致富金融(临时代码)官员(CFO),任职日期为2024年9月30日。Niven在ANZ、UBS和Ord Minett的私人财富管理等之前的职务中积累了丰富经验,并为各种上市和非上市公司提供治理、财务和公司结构咨询。她毕业于西澳大学商学和科学专业,并是特许金融分析师。Niven接替了自2023年12月以来担任临时CFO的Phillip Hains,并将继续担任公司秘书。Alterity的主要资产ATH434目前正在进行两项针对多系统萎缩症治疗的2期临床试验,该公司还拥有广泛用于神经疾病的药物发现平台。该公告由CEO David Stamler授权发出,附有关于公司药物开发计划的前瞻性声明。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息